v3.23.1
Collaborations (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Collaborative and license agreements      
AbbVie's receivable from Janssen $ 11,473   $ 11,254
AbbVie's payable to Janssen 24,789   25,402
Janssen Biotech Inc. | Collaborative arrangement      
Collaborative and license agreements      
Milestone payments $ 200    
Share of collaboration development costs responsible by Janssen (as a percent) 60.00%    
Share of collaboration development costs responsible by the entity (as a percent) 40.00%    
Global - AbbVie's share of other costs (included in respective line items) $ 55 $ 64  
AbbVie's receivable from Janssen 267   295
AbbVie's payable to Janssen 293   $ 379
Janssen Biotech Inc. | Collaborative arrangement | United States      
Collaborative and license agreements      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 297 408  
Janssen Biotech Inc. | Collaborative arrangement | International      
Collaborative and license agreements      
International - AbbVie's share of profits (included in net revenues) 240 299  
Genentech, Inc. | Collaborative arrangement      
Collaborative and license agreements      
Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold) 202 178  
AbbVie's share of development costs (included in R&D) 28 27  
Genentech, Inc. | Collaborative arrangement | United States      
Collaborative and license agreements      
AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A) $ 11 $ 12